WeightWatchers emerges from bankruptcy after slimming down debts
The company said it was shaking up its leadership team and launching a new menopause programme.
The group filed for bankruptcy in the US in May in order to eliminate 1.15 billion US dollars (£840 million) worth of debt on its balance sheet.
The court process enabled it to restructure its finances and write off the debts, which made up more than 70% of the total amount, while agreeing new terms to pay back its lenders.
WeightWatchers' chief executive Tara Comonte had said it needed to transform amid a 'rapidly evolving weight managing landscape'.
Competition has grown fiercely with demand for prescription weight-loss injections under brand names like Mounjaro and Wegovy growing, while studies into the long-term effects of the jabs are ongoing.
On Tuesday, the group said it had appointed a new chief medical officer, physician Dr Kim Boyd, to lead the integration of emerging science into its wider lifestyle-based offering for members.
Dr Boyd said she planned to expand the company's 'legacy' by 'combining the best tools of modern medicine, like GLP-1s, with science-backed lifestyle change and the power of community to deliver better outcomes'.
GLP-1s, the scientific term for weight-loss jabs, work by reducing food cravings.
WeightWatchers recently partnered with anti-obesity drugs provider CheqUp in the UK so patients taking the medication can access its 'companion' diet and lifestyle support app.
Ms Comonte said it was a 'pivotal moment for the group, adding: 'With renewed financial strength, an expanded leadership team, and the addition of Dr Kim Boyd to lead clinical strategy and programme innovation, we're accelerating our transformation.
'In a landscape dominated by noise, quick fixes, and conflicting advice, WeightWatchers continues to lead as the most trusted, science-backed platform, proven to drive better results and lasting impact.'
The restructuring resulted in the company appointing a new board of directors.
It also revealed it would be launching a new programme later this year to support women through perimenopause, menopause, and postmenopause, through tailored nutritional and behavioural strategies.
The move will help it address a broader gap in healthcare and meet the evolving needs of millions of its members around the world, it said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Popular weight-loss drugs linked to sudden vision loss, research suggests
New research has discovered certain weight-loss medications could be associated with an increased risk of serious eye conditions, and even vision loss. Two studies, published in JAMA, analyzed how semaglutide and tirzepatide — which include popular drugs like Ozempic, Wegovy, Mounjaro and Zepbound — impacted eye health in Americans with type 2 diabetes over a two-year period. One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN) – a rare eye condition that can lead to sudden vision loss due to lack of blood flow – in association with semaglutide and tirzepatide. Popular Weight-loss Medication Could Relieve Painful Arthritis Symptoms, Doctors Report Out of more than 159,000 study participants with type 2 diabetes, 35 developed NAION, compared to 19 people in the comparison group. The Ohio-based researchers also noted an increased risk of developing "other optic nerve disorders," identified in 93 patients. Read On The Fox News App Although the second study did not observe a "statistically significant difference" in NAION in GLP-1 drug users, there was a small increase in diabetic retinopathy, an eye disease that can damage the retina. Diabetic Patients Taking Glp-1s May Face Increased Risk Of Eye Disease, Study Suggests While individuals with type 2 diabetes on GLP-1s showed a modestly increased risk of diabetic retinopathy, the researchers concluded that fewer patients experienced sight-threatening complications from the disease. "These findings suggest that all patients with type 2 diabetes treated with GLP-1 RAs, regardless of preexisting diabetic retinopathy, should be regularly screened and monitored for potential complications," the study authors concluded. Sue Decotiis, M.D., a medical weight loss doctor in New York City, said she believes more studies are required to confirm the association between these drugs and vision loss, as these studies report some conflicting results. "NAION is a rare condition of the optic nerve that, although serious, has not really been shown to be increased by these studies," Decotiis, who was not involved in the research, told Fox News Digital. "We need more studies for certain." Diabetic patients already face a high incidence of eye disease related to blood flow and nerve damage, the expert noted. "Eye complications are often directly related to the degree or lack thereof of diabetes control." Click Here To Sign Up For Our Health Newsletter In most cases, GLP-1 drugs reduce the severity of type 2 diabetes, therefore reducing the incidence of eye diseases, Decotiis noted. These drugs have also been shown to reduce the risk of cardiovascular disease, like hypertension, and to improve circulation, which can improve eye health. For diabetics who are starting a GLP-1, Decotiis recommends having an exam done by an ophthalmologist and scheduling follow-up exams throughout treatment. "We should take precaution with methodical ophthalmic care for diabetics on these drugs," Decotiis said. "However, let's not throw the baby out with the bath water." For more Health articles, visit Novo Nordisk, maker of Ozempic and Wegovy, provided the following statement when contacted by Fox News Digital. "Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from the use of our medicines very seriously. NAION is a very rare eye disease, and it is not an adverse drug reaction for the marketed formulations of semaglutide (Ozempic, Rybelsus and Wegovy) as per the approved labels in the U.S." "Novo Nordisk, on its part, has conducted an analysis across randomized controlled clinical trials with GLP-1 receptor agonists, including a blinded ophthalmologist evaluation to confirm NAION diagnoses. Our current assessment is that these data do not suggest a causal relationship between GLP-1 RA use and NAION events."Original article source: Popular weight-loss drugs linked to sudden vision loss, research suggests Solve the daily Crossword
Yahoo
18 hours ago
- Yahoo
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating profit growth, resulting in a decline in its share price. The downgrade stems from weaker-than-expected momentum for its semaglutide-based obesity and diabetes drugs, Wegovy and Ozempic, especially in the U.S. obesity market. Despite the FDA ending its compounding grace period in May 2025, the company reported that illegal sales of counterfeit semaglutide persist under the pretext of personalization, hampering Wegovy's uptake. In response, the company is pursuing litigation and regulatory action to protect patients and market share. Wegovy's adoption has also been slower than anticipated in both cash and insured channels, despite efforts through NovoCare Pharmacy and telehealth partnerships. Market expansion has lagged, and competition in the GLP-1 obesity segment, especially from NVO's arch-rival, Eli Lilly LLY, has intensified. LLY markets its tirzepatide injections as Mounjaro for diabetes and Zepbound for obesity. Despite being on the market for a shorter duration, Lilly's Mounjaro and Zepbound have witnessed strong sales driven by rapid demand. Ozempic is also facing similar competitive pressures in the U.S. diabetes market, while international launches of Wegovy are experiencing uneven uptake across obesity markets. However, following a major pipeline setback for Eli Lilly, Novo Nordisk stock is staging a modest recovery, as is evident by the 5.8% gain in share price so far in August. Last week, LLY reported underwhelming efficacy results from the ATTAIN-1 study, the first of two pivotal phase III studies of its oral GLP-1 candidate, orforglipron, resulting in a significant drop in the stock price, given its strategic importance within Lilly's obesity pipeline. Investor sentiment was further dampened by the study's high patient discontinuation rates, stemming from both side effects and personal reasons, raising doubts about orforglipron's long-term utility in chronic obesity management. This presents a significant opportunity for Novo Nordisk to bounce back. NVO is making good progress with its pipeline, which includes several other new candidates for diabetes and obesity. The company also has strong fundamentals, and the untapped nature of the obesity market makes us believe that the stock has significant upside potential in the future. Let's dig deeper and understand the company's strengths and weaknesses to understand how to play the stock. Semaglutide – Still NVO's Primary Top-Line Driver Novo Nordisk's success in recent years has been driven by the sales of Ozempic (injection) and Rybelsus (oral) for diabetes, and Wegovy for obesity. Despite its recent market turmoil, the company holds a strong position in diabetes care, with one of the industry's broadest portfolios. Wegovy is a major revenue driver, recording sales of $5.41 billion (DKK 36.9 billion) during the first half of 2025, up 78% year over year on strong prescription growth. Ozempic also continues to boost overall revenues. To protect its lead amid competition from Lilly, Novo Nordisk is heavily investing in its GLP-1 manufacturing capacity. As of July 1, CVS Caremark, a major pharmacy benefit manager, has designated Wegovy as its preferred GLP-1 therapy for weight loss. Novo Nordisk is expanding semaglutide's reach through new indications. Wegovy is now approved for reducing major cardiovascular events, easing HFpEF symptoms, and relieving osteoarthritis-related knee pain in obesity. Ozempic's label includes use in diabetes patients with cardiovascular and kidney diseases. The FDA is reviewing Novo Nordisk's application for a 25 mg oral semaglutide for obesity, with a decision expected by year-end. Oral pills could boost adherence over injections. Potential approval would give Novo Nordisk a notable advantage as the sole manufacturer of a marketed oral obesity pill, positioning it to capture significant market share. NVO has also filed Rybelsus for cardiac event prevention in diabetes patients. A 7.2 mg Wegovy dose, showing up to 25% weight loss in the STEP UP study, is under EU review. Label expansion is also being sought for Ozempic in treating peripheral artery disease in the United States and the EU. Beyond its GLP-1 portfolio, Novo Nordisk is broadening its presence in rare diseases. The company is advancing regulatory plans for Mim8 in hemophilia A and has secured EU approval for Alhemo to treat hemophilia A and B with inhibitors. Alhemo is also under EU review for patients without inhibitors. In the United States, the therapy is already approved for both hemophilia A and B, with or without inhibitors. It also expects to file for semaglutide to treat metabolic dysfunction–associated steatohepatitis in both the United States and the EU in 2025. NVO Focuses on Next-Generation Drugs for Obesity Novo Nordisk is also developing several next-generation obesity candidates in its pipeline, especially targeting the lucrative U.S. market. The most advanced weight loss candidate in Novo Nordisk's pipeline is CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy. The company is planning its regulatory submission in 2026. Novo Nordisk is also developing a small-molecule oral CB1 inverse agonist, monlunabant, in a mid-stage study. The company is currently gearing up to advance Amycretin, an investigational unimolecular GLP-1 and amylin receptor agonist, for weight management into late-stage development. The phase III program on amycretin is planned to be initiated during the first quarter of 2026. Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, diabetes and other cardiometabolic diseases. Competition Heating Up in the Obesity Space Competition in the obesity market is heating up as the obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Lilly and Novo Nordisk presently dominate the market. Several other companies, like Amgen AMGN and Viking Therapeutics VKTX, are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and diabetes, with the first two phase III studies initiated in March. Viking Therapeutics started two late-stage studies evaluating the subcutaneous formulation of its investigational obesity drug, VK2735. VKTX is also evaluating an oral version of this obesity drug in an ongoing mid-stage study, with a data readout expected later this year. NVO's Stock Price, Valuation, Estimates Year to date, Novo Nordisk shares have lost 42.1% compared with the industry's 8% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading below its 50 and 200-day moving averages. NVO Stock Underperforms the Industry, Sector & the S&P 500 Image Source: Zacks Investment Research Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 12.12 forward earnings, which is lower than 13.73 for the industry. The stock is trading much below its five-year mean of 29.25. NVO Stock Valuation Image Source: Zacks Investment Research Earnings estimates for 2025 have improved from $3.86 to $3.89 per share over the past seven days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have improved from $4.20 to $4.24. NVO Estimate Movement Image Source: Zacks Investment Research The stock's return on equity on a trailing 12-month basis is 78.64%, which is higher than 34.32% for the large drugmaker industry, as seen in the chart below. NVO Return on Equity Image Source: Zacks Investment Research Here's How to Play NVO Stock Novo Nordisk, currently carrying a Zacks Rank #3 (Hold), remains a strong long-term player in diabetes and obesity care despite recent guidance cuts and competitive pressures. The company holds a dominant GLP-1 market position, with Wegovy and Ozempic delivering strong double-digit sales growth and benefiting from expanding indications. A potential FDA approval for 25 mg oral semaglutide for obesity by year-end could give NVO a first-to-market edge, improving adherence and broadening its reach. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Competition from Eli Lilly remains intense, but Lilly's recent setback with oral candidate orforglipron has pivoted investor sentiment toward NVO. The company's deep pipeline, including next-generation obesity candidates like CagriSema and Amycretin, along with rare disease therapies such as Mim8 and Alhemo, offers broad potential for market expansion. Manufacturing expansions and strategic deals, including a $2.2 billion Septerna partnership, also support long-term growth. Given these strengths, current holders may retain their positions, while long-term investors could use the current price as an entry point. Near-term volatility is likely due to competition, uneven Wegovy uptake internationally, and legal action over counterfeit semaglutide, making it less attractive for short-term trading. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Yahoo
Eli Lilly Fires Up GLP-1 Race in India With Mounjaro Pen Launch
Eli Lilly (NYSE:LLY) has rolled out its best-selling diabetes drug Mounjaro in a new injector pen format in India, intensifying its battle with Novo Nordisk in the fast-growing GLP-1 market. The Mounjaro Kwikpen, approved in June for six dose strengths from 2.5 mg to 15 mg, starts at ?14,000 ($160) for the lowest dose and rises to ?27,500 for the highest. Novo Nordisk's (NYSE:NVO) Wegovy, launched just days earlier in a similar format, is priced nearly in line across comparable doses. Warning! GuruFocus has detected 4 Warning Signs with VG. Lilly first entered India's obesity and diabetes market in March with Mounjaro vials and has already seen rapid uptake sales jumped 60% in May from April, according to Pharmarack Technologies. With both companies now offering user-friendly injector pens, competition is set to heat up in a country with more than 100 million diabetics and a rising obesity burden. Analysts see India as a key growth market for GLP-1 drugs as lifestyle diseases climb and awareness of newer therapies expands. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
